ZS Pharma is a biopharmaceutical company committed to the development and commercialization of highly selective, non-systemically absorbed therapeutics to treat renal, cardiovascular, liver and metabolic diseases. Our initial focus is on the development of sodium zirconium cyclosilicate (ZS-9), a highly selective inorganic cation exchanger designed to entrap excess potassium throughout the gastrointestinal tract. ZS-9 is being developed for the treatment of hyperkalemia, a potentially life-threatening condition characterized by abnormally high levels of potassium in the blood. ZS-9 has successfully completed three pivotal prospective, randomized, double-blind, placebo-controlled studies. On the basis of these studies, we plan to submit for approval of ZS-9 for the treatment of hyperkalemia with the US FDA and European Medicines Agency (EMEA) in the first half of 2015.
Keep up to date with the latest ZS Pharma News and Updates
ZS Pharma Announces Upsizing and Pricing of $186 Million Public Offering of Common StockDownload PDF
ZS Pharma Announces Proposed Public Offering of Common StockDownload PDF
ZS Pharma to Present Data from Phase 3 Trials of ZS-9 in Presentations at the National Kidney Foundation 2015 Spring Clinical MeetingsDownload PDF